ARAV(Delisted)
AraviveยทNASDAQ
--
--(--)
ARAV Profile
Aravive, Inc.
A late clinical-stage oncology company that develops targeted therapeutics to treat metastatic disease
River Oaks Tower, 3730 Kirby Drive, Suite 1200, Houston, Texas 77098
--
Aravive, Inc. (Nasdaq: ARAV effective October 16, 2018) is a clinical-stage biotechnology company focused on the development of innovative therapies for cancer survival pathways. Aravive's main candidate, AVB-S6-500, is a novel high-affinity soluble Fc fusion protein designed to block the activation of the GAS 6-AXL signaling pathway by intercepting the binding of GAS 6 to its receptor AXL. AXL receptor signaling plays an important role in treatment resistance and immunosuppression in many types of malignancies by hindering cancer cell survival. Aravive expects to initiate the Phase 1b portion of the Phase 1b/2 clinical trial of AVB-S6-500 in combination with standard treatment for platinum-resistant ovarian cancer patients by the end of 2018, and intends to develop it into a new anti-tumor business.
